Skip to main content
    A

    Aprea Therapeutics Inc (APRE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.62
    +0.03 (+5.93%)

    Market Cap: $7.55M

    Last updated: Oct 16, 2026 at 1:54 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    64%(18/28)
    Avg Surprise
    -5.09%
    Streak
    3 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.08
    Range$-0.09 - $-0.07
    2 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$-0.23+65.2%
    60d ago$-0.23+65.2%
    30d ago$-0.23+65.2%
    7d ago$-0.07-9.1%
    Current$-0.08
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.20
    Range$0.14 - $0.25
    2 analysts
    Revenue Consensus
    $-126500
    Range$-126500 - $-126500
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.20---
    Sep 26EST
    		-$-0.08---
    Jun 26
    Reported Aug 12
    		$-0.07N/A+68.18%Beat+86.8%
    Mar 26
    Reported May 13
    		$-0.22$-0.23+4.35%Beat+66.5%
    Dec 25
    Reported Mar 16
    		$-0.32$-0.36+11.11%Beat+34.7%
    Sep 25
    Reported Nov 12
    		$-0.47$-0.34-38.24%Miss+26.6%
    Jun 25
    Reported Aug 12
    		$-0.53$-0.71+25.35%Beat+8.6%
    Mar 25
    Reported May 14
    		$-0.66$-1.00+34.39%Beat+2.1%
    Dec 24
    Reported Mar 25
    		$-0.49$-0.54+9.26%Beat+46.7%
    Sep 24
    Reported Nov 7
    		$-0.64$-0.74+13.51%Beat+25.6%
    Jun 24
    Reported Aug 12
    		$-0.58$-0.60+3.33%Beat+33.3%
    Mar 24
    Reported May 14
    		$-0.67$-0.80+16.25%Beat+50.0%
    Dec 23
    Reported Mar 26
    		$-0.92$-0.77-19.48%Miss+0.0%
    Sep 23
    Reported Nov 9
    		$-0.86$-1.04+17.31%Beat+64.2%
    Jun 23
    Reported Aug 10
    		$-0.87$-1.38+36.96%Beat+95.6%
    Mar 23
    Reported May 15
    		$-1.34$-0.82-63.41%Miss+81.4%
    Dec 22
    Reported Mar 30
    		$-0.92N/A+70.13%Beat+87.2%
    Sep 22
    Reported Nov 9
    		$-2.40$-1.60-50.00%Miss+73.3%
    Jun 22
    Reported Aug 11
    		$-19.63$-6.20-216.61%Miss-104.5%
    Mar 22
    Reported May 16
    		$-7.20$-7.60+5.26%Beat+21.7%
    Dec 21
    Reported Mar 15
    		$-7.20$-8.80+18.18%Beat+50.7%
    Sep 21
    Reported Nov 8
    		$-9.00$-9.05+0.55%Beat+22.4%
    Jun 21
    Reported Aug 12
    		$-9.60$-9.35-2.67%Miss+38.5%
    Mar 21
    Reported May 6
    		$-9.20$-9.85+6.60%Beat-2.2%
    Dec 20
    Reported Mar 16
    		$-14.60$-12.85-13.62%Miss-14.1%
    Sep 20
    Reported Nov 5
    		$-11.60$-15.20+23.68%Beat+89.0%
    Jun 20
    Reported Aug 11
    		$-15.60$-12.05-29.46%Miss-4932.3%
    Mar 20
    Reported May 15
    		$-9.00$-11.35+20.70%Beat-
    Dec 19
    Reported Mar 26
    		$-12.80$-8.00-60.00%Miss-
    Sep 19
    Reported Oct 3
    		$-105.80$-78.87-34.14%Miss-
    Jun 19
    Reported Aug 28
    		$-0.31$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.57EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-255026.00%
    ROE-46.20%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio13.55xQuick Ratio13.55x
    Trading Statistics
    Beta1.63Avg Volume245.12K
    52-Week High$1.6952-Week Low$0.55

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.62
    SMA 20$0.69
    SMA 50$0.73
    SMA 200$0.77
    EMA 10$0.63
    EMA 20$0.67
    EMA 50$0.71
    EMA 200$0.84

    MACD

    Line: -0.04Signal: -0.03Hist: -0.01

    ADX

    ADX: 22.6+DI: 19.0-DI: 23.1

    Aroon & PSAR

    Aroon Up8.0
    Aroon Down80.0
    PSAR$0.69

    Bollinger Bands

    Upper Band$0.84
    Lower Band$0.53
    %B Position4516%(Upper)
    Band Width0.28

    RSI (14-Day)

    Neutral
    40.3

    Momentum Oscillators

    Stoch %K18.6
    Stoch %D17.5
    Williams %R-75.0
    ROC (10d)-14.6%
    Momentum-0.11
    CCI (20d)-77.0
    MFI (14d)23.0

    Volatility Measures

    ATR (14d)$0.06(9.2%)
    StdDev (20d)0.08
    Hist Vol65.9%(High)

    Volume Flow

    VWAP$0.61
    OBV119.6M
    AD Line-66.9M
    CMF (20d)-0.338

    Volume Metrics

    Avg Vol (20d)254.5K
    Vol Ratio0.3x(Low)
    VWMA (20d)$0.70

    Pivot Points

    R3$0.63
    R2$0.62
    R1$0.60
    Pivot Point$0.59
    S1$0.57
    S2$0.56
    S3$0.54

    Advanced Oscillators

    TSI-25.16
    Ultimate Osc39.7
    KST-163.48

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$3,337$1,848$118,111$162,463$205,817$354,621$561,574$380,569$14,075$319,468
    Cost of Revenue$0$0$-4,378,993$0$0$0$2.36M$0$0$0$2.05M$0
    Gross Profit$0$0$3,337$1,848$118,111$162,463$205,817$354,621$561,574$380,569$14,075$319,468
    Operating Expenses$4.03M$3.43M$2.65M$3.12M$3.51M$4.25M$3.43M$4.45M$4.41M$3.53M$3.69M$3.84M
    R&D$2.46M$1.61M$1.01M$1.64M$1.91M$2.48M$2.36M$2.85M$2.56M$1.60M$2.05M$2.12M
    SG&A$1.57M$1.82M$1.64M$1.48M$1.59M$1.76M$1.07M$1.61M$1.85M$1.93M$1.64M$1.72M
    Operating Income$-4,032,180$-3,430,412$-2,643,093$-3,117,388$-3,387,773$-4,085,582$-3,226,045$-4,097,016$-3,846,924$-3,149,670$-3,674,929$-3,522,850
    Interest Income$358,923$134,784$118,664$150,669$178,027$204,726$274,626$348,741$382,374$283,403$310,287$321,215
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-3,591,304$-3,287,917$-2,455,630$-2,972,410$-3,238,870$-3,932,659$-2,894,799$-3,783,769$-3,470,052$-2,810,091$-3,443,254$-3,204,515
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-3,591,304$-3,287,917$-2,455,630$-2,972,410$-3,238,870$-3,932,659$-2,894,799$-3,783,769$-3,470,052$-2,810,091$-3,443,254$-3,204,515
    EBITDA$-3,944,481$-3,417,273$-2,568,865$-3,117,650$-3,411,469$-4,131,956$-3,163,997$-4,127,081$-3,847,122$-3,087,337$-3,748,555$-3,524,298
    EBIT$-3,950,227$-3,422,701$-2,574,294$-3,123,079$-3,416,897$-4,137,385$-3,169,425$-4,132,510$-3,852,426$-3,093,494$-3,753,541$-3,525,730
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about APRE

    News

    Ladenburg Thalmann Initiates Aprea Therapeutics(APRE.US) With Buy Rating, Announces Target Price $2

    Ladenburg Thalmann has initiated coverage on Aprea Therapeutics (APRE.US) with a Buy rating. The firm has set a target price of $2 for the stock.

    Moomoo•10/15/26•Bullish

    Two consecutive conference days put Aprea's CEO in a fireside chat and panel.

    Aprea Therapeutics (APRE) announced that President and CEO Oren Gilad will participate in two October 2026 conferences...

    Stock Titan•10/6/26•Neutral

    Aprea Therapeutics to Present at October Conferences

    Aprea Therapeutics, a clinical-stage precision medicine oncology company, announced that its President and CEO, Oren Gilad PhD, will participate in two upcoming October conferences...

    Yahoo! Finance Canada•10/5/26•Somewhat-Bullish

    Aprea to Present Updated APR-1051 Cancer Trial Data

    Aprea Therapeutics (NASDAQ: APRE) will present updated interim results from its Phase 1 trial of WEE1 inhibitor APR-1051 in November. The data will be shared at the 38th EORTC-NCI-AACR Symposium on Molecular Targets...

    MyChesCo•9/28/26•Somewhat-Bullish

    Aprea Therapeutics to present WEE1 inhibitor trial data in November

    Aprea Therapeutics will present updated interim results from its Phase 1 ACESOT-1051 study of the WEE1 inhibitor APR-1051 at the 38th EORTC-NCI-AACR Symposium in Barcelona on November 20...

    Investing.com•9/22/26•Somewhat-Bullish

    APRE Valuation and Fair Value

    P/E
    -0.6x
    P/B
    0.9x
    See GNG's fair value

    APRE Profitability: Margins, ROIC and FCF

    Operating margin
    -255026.0%
    Net margin
    0.0%
    ROE
    -46.2%
    FCF margin
    -234677.2%

    APRE Competitors

    CompanyTicker
    Senti Biosciences IncSNTI
    Soligenix Inc.SNGX
    Tenon Medical IncTNON
    XWELL Inc.XWEL
    Collplant Biotechnologies LtdCLGN
    InMed Pharmaceuticals IncINM
    CNS Pharmaceuticals IncCNSP
    Predictive Oncology IncPOAI

    Sector: Healthcare

    APRE Analyst Ratings

    Consensus
    Buy
    Analysts
    3
    Strong Buy
    1
    Buy
    2
    Hold
    0
    Sell
    0
    Strong Sell
    0

    APRE Bull Case vs Bear Case

    Bull case

    • APRE beat EPS estimates in 87.5% of its last 8 reported quarters.

    Bear case

    • APRE's quarterly revenue changed -98.4% year over year.

    APRE Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    16.0%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.08
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About APRE

    Does APRE pay dividends?

    Aprea Therapeutics Inc (APRE) does not currently pay a regular dividend.

    What is APRE's market cap?

    Aprea Therapeutics Inc (APRE) has a market capitalization of $7.55M with a current stock price of $0.62.

    Related stocks

    Sector: Healthcare

    All stocks starting with A

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In